1. Home
  2. STVN vs CPRX Comparison

STVN vs CPRX Comparison

Compare STVN & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$17.50

Market Cap

3.7B

ML Signal

HOLD

Logo Catalyst Pharmaceuticals Inc.

CPRX

Catalyst Pharmaceuticals Inc.

HOLD

Current Price

$31.23

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STVN
CPRX
Founded
1949
2002
Country
Italy
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.4B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
STVN
CPRX
Price
$17.50
$31.23
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$25.67
$35.00
AVG Volume (30 Days)
500.4K
3.0M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
0.39%
N/A
EPS Growth
N/A
28.24
EPS
N/A
0.50
Revenue
N/A
$119,072,803.00
Revenue This Year
$9.67
$9.20
Revenue Next Year
$9.99
$10.51
P/E Ratio
$27.15
$62.42
Revenue Growth
N/A
16.39
52 Week Low
$12.89
$19.05
52 Week High
$28.00
$32.56

Technical Indicators

Market Signals
Indicator
STVN
CPRX
Relative Strength Index (RSI) 56.51 73.13
Support Level $13.58 $22.24
Resistance Level $19.05 $31.29
Average True Range (ATR) 0.78 0.46
MACD -0.10 -0.04
Stochastic Oscillator 40.84 97.66

Price Performance

Historical Comparison
STVN
CPRX

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Share on Social Networks: